RT @rincondesisifo: (Cochrane) Seguridad y eficacia del adalimumab en pac con enfermedad de Crohn https://t.co/mPdscp1zlK https://t.co/fQBc…
(Cochrane) Seguridad y eficacia del adalimumab en pac con enfermedad de Crohn https://t.co/mPdscp1zlK https://t.co/fQBcVbHFPa
RT @CochraneLibrary: Adalimumab for maintenance of remission in Crohn's disease https://t.co/8rWRBZzdK6 Cochrane systematic review includes…
RT @CochraneLibrary: Adalimumab for maintenance of remission in Crohn's disease https://t.co/8rWRBZzdK6 Cochrane systematic review includes…
RT @CochraneLibrary: Adalimumab for maintenance of remission in Crohn's disease https://t.co/8rWRBZzdK6 Cochrane systematic review includes…
RT @CochraneLibrary: Adalimumab for maintenance of remission in Crohn's disease https://t.co/8rWRBZzdK6 Cochrane systematic review includes…
Adalimumab for maintenance of remission in Crohn's disease https://t.co/8rWRBZzdK6 Cochrane systematic review includes six studies with 1158 participants.
RT @cochrane_nz: Adalimumab for maintenance of remission in Crohn's disease https://t.co/Lt0W7c74h3 Cochrane systematic review includes six…
Adalimumab for maintenance of remission in Crohn's disease https://t.co/Lt0W7c74h3 Cochrane systematic review includes six studies with 1158 participants. https://t.co/BcjVqv70cm
RT @Cochrane_US: Adalimumab for maintenance of remission in Crohn's disease https://t.co/qziBDNfCfD Cochrane systematic review includes six…
Adalimumab for maintenance of remission in Crohn's disease https://t.co/qziBDNfCfD Cochrane systematic review includes six studies with 1158 participants.
Adalimumab for maintenance of remission in Crohn's disease. Read the latest @CochraneLibrary systematic review, including six studies with 1,158 participants. https://t.co/oouNR56TWc #crohnsdisease https://t.co/TQWeBoXcdz